Crispr Therapeutics (CRSP) | Stock Overview & Key Data
Crispr Therapeutics Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $220.20 on January 11, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Crispr Therapeutics CRSP | 3.93B Mid-cap | 13.01% | 30.24% | 75.31% | 32.77% | 32.32% | -11.59% | -38.61% | -44.57% |
| Vertex VRTX | 114.06B Large-cap | 3.14% | 4.53% | -1.27% | 13.16% | 14.93% | -6.00% | 56.88% | 55.98% |
| Regeneron REGN | 55.27B Large-cap | 2.40% | 5.82% | -1.63% | -25.33% | -23.41% | -51.08% | -11.43% | -16.45% |
| Blueprint Medicines BPMC | 8.29B Mid-cap | 0.05% | 0.34% | 62.08% | 41.67% | 47.25% | 9.02% | 139.78% | 65.31% |
| Roivant Sciences ROIV | 7.82B Mid-cap | -0.73% | -1.99% | 19.60% | -1.45% | -10.10% | -5.37% | 151.52% | 8.27% |
| Bio-Techne TECH | 7.92B Mid-cap | 1.15% | 5.61% | 7.93% | -29.94% | -26.30% | -33.33% | -40.13% | -26.31% |
Ownership & Short Interest
Crispr Therapeutics Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Crispr Therapeutics would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
In the last 52 weeks, Crispr Therapeutics reached a high of $63.68 (on July 16, 2024) and a low of $30.04 (on April 7, 2025).
Curious about Crispr Therapeutics's size and valuation? Its market capitalization stands at 3.93B. When it comes to valuation, the P/E ratio (trailing twelve months) is -10.50, and the forward P/E (looking ahead) is -9.04.
As for dividends, Crispr Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
When looking at Crispr Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX114.06B Healthcare Biotechnology -6.00% 56.88% Regeneron
REGN55.27B Healthcare Biotechnology -51.08% -11.43% Blueprint Medicines
BPMC8.29B Healthcare Biotechnology 9.02% 139.78% Roivant Sciences
ROIV7.82B Healthcare Biotechnology -5.37% 151.52% Bio-Techne
TECH7.92B Healthcare Biotechnology -33.33% -40.13% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
To get a sense of Crispr Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -19.71%, the Debt to Equity ratio from the most recent quarter is 11.99, and its Gross Profit Margin stands at N/A.
Looking at Crispr Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $38M. Compared to the same quarter last year (YoY), quarterly revenue grew by 71.60%, and quarterly earnings saw a YoY growth of N/A.
Wondering who owns Crispr Therapeutics stock? Company insiders (like executives and directors) hold about 1.76% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 76.58%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.